©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 113172
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113172
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.113172
Table 4 Univariate analysis of biomarker intensities: Comparison of biological treatment initiation by 1 year
| No biologic treatment (n = 75) | Biologic treatment (n = 48) | P value | |
| Female, n (%) | 33 (44.0) | 12 (25.0) | 0.052 |
| Ethnicity, n (%) | 0.56 | ||
| Western European | 50 (66.7) | 34 (70.8) | |
| South Asian | 13 (17.3) | 5 (10.4) | |
| Other | 12 (16.0) | 9 (18.8) | |
| Age (year) | 13.0 ± 3.07 | 12.5 ± 2.39 | 0.353 |
| Biomarker | |||
| CCL2 | 104 ± 37.1 | 105 ± 54.1 | 0.937 |
| CCL5 | 1722 ± 770 | 1798 ± 1479 | 0.742 |
| CCL7 | 283 ± 138 | 269 ± 108 | 0.532 |
| IL-8 | 40.5 ± 217 | 15.1 ± 13.4 | 0.316 |
| TSLP | 308 ± 106 | 286 ± 128 | 0.323 |
| CCL3 | 44.2 ± 11.9 | 46.2 ± 17.3 | 0.498 |
| CXCL1 | 297 ± 257 | 415 ± 330 | 0.039 |
| CXCL2 | 176 ± 204 | 241 ± 201 | 0.083 |
| CXCL9 | 4087 ± 3470 | 4102 ± 2828 | 0.979 |
| IL-18 | 137 ± 123 | 214 ± 280 | 0.08 |
| IL-22 | 64.9 ± 233 | 43.8 ± 16.0 | 0.438 |
| TARC | 379 ± 641 | 288 ± 146 | 0.238 |
- Citation: Eindor-Abarbanel A, Tsai K, Sandhu A, Vallance B, Jacobson K. Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease. World J Gastroenterol 2025; 31(46): 113172
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/113172.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.113172